"Antibodies, Monoclonal" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antibodies produced by a single clone of cells.
| Descriptor ID |
D000911
|
| MeSH Number(s) |
D12.776.124.486.485.114.224 D12.776.124.790.651.114.224 D12.776.377.715.548.114.224
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antibodies, Monoclonal".
Below are MeSH descriptors whose meaning is more specific than "Antibodies, Monoclonal".
This graph shows the total number of publications written about "Antibodies, Monoclonal" by people in this website by year, and whether "Antibodies, Monoclonal" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 6 | 7 |
| 1997 | 5 | 11 | 16 |
| 1998 | 4 | 7 | 11 |
| 1999 | 4 | 4 | 8 |
| 2000 | 5 | 8 | 13 |
| 2001 | 4 | 10 | 14 |
| 2002 | 7 | 15 | 22 |
| 2003 | 6 | 15 | 21 |
| 2004 | 5 | 10 | 15 |
| 2005 | 13 | 10 | 23 |
| 2006 | 11 | 7 | 18 |
| 2007 | 11 | 9 | 20 |
| 2008 | 15 | 15 | 30 |
| 2009 | 21 | 7 | 28 |
| 2010 | 17 | 7 | 24 |
| 2011 | 17 | 15 | 32 |
| 2012 | 7 | 11 | 18 |
| 2013 | 12 | 10 | 22 |
| 2014 | 17 | 8 | 25 |
| 2015 | 18 | 12 | 30 |
| 2016 | 21 | 13 | 34 |
| 2017 | 31 | 13 | 44 |
| 2018 | 36 | 8 | 44 |
| 2019 | 20 | 11 | 31 |
| 2020 | 16 | 20 | 36 |
| 2021 | 20 | 18 | 38 |
| 2022 | 4 | 22 | 26 |
| 2023 | 8 | 17 | 25 |
| 2024 | 11 | 8 | 19 |
| 2025 | 17 | 8 | 25 |
| 2026 | 3 | 1 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antibodies, Monoclonal" by people in Profiles.
-
Efficacy and Tolerability of Topotecan/Cyclophosphamide/Dinutuximab in Relapsed and Refractory High-Risk Neuroblastoma: A Multi-Institutional Retrospective Study. Pediatr Blood Cancer. 2026 May; 73(5):e70195.
-
Epitope-focused discovery of SARS-CoV-2 antibodies that potently neutralize Omicron variants. Nat Microbiol. 2026 Apr; 11(4):1113-1132.
-
Emapalumab use in malignancy-associated hemophagocytic lymphohistiocytosis in the United States: the REAL-HLH study. Blood Adv. 2026 Mar 10; 10(5):1564-1575.
-
Structural basis for recognition of Rift Valley fever virus Gn protein by a human neutralizing monoclonal antibody with a kappa light chain. PLoS Pathog. 2026 Feb; 22(2):e1013926.
-
Severe Flash Pulmonary Edema Following Rituximab and Daratumumab Infusion for Post-Transplant Antibody-Mediated Rejection. Pediatr Transplant. 2025 12; 29(8):e70230.
-
A protective and heterosubtypic antibody lineage targeting the influenza A virus neuraminidase active site. J Clin Invest. 2025 Dec 01; 135(23).
-
Mouse-adapted SARS-CoV-2 Omicron BA.5 infection induces post-acute lung fibrosis in BALB/c mice. J Virol. 2025 11 25; 99(11):e0140625.
-
Ultrapotent human antibodies lock E protein dimers central region of diverse DENV3 morphological variants. Nat Commun. 2025 Oct 16; 16(1):9182.
-
Non-neutralizing antibodies to influenza A matrix-protein-2-ectodomain are broadly effective therapeutics and resistant to viral escape mutations. Sci Adv. 2025 Sep 12; 11(37):eadx3505.
-
Mature dengue virus particles inactivated by a non-ionic detergent retain quaternary neutralizing epitopes and induce potent neutralizing antibodies. Front Immunol. 2025; 16:1626823.